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INTRODUCTION
Allogeneic bone marrow transplantation (BMT) is the
only proven curative therapy for patients with chronic myel-
ogenous leukemia (CML). Transplantation with marrow
grafts from human leukocyte antigen (HLA)-identical sibling
donors has resulted in long-term disease-free survival rates of
45–80% for patients in chronic phase and 10–50% for
patients transplanted in the more advanced phases of the dis-
ease [1–4]. Most CML patients who are potential candidates
for allogeneic BMT, however, lack an HLA-identical sibling.
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ABSTRACT
Some older patients (40 years) with chronic myelogenous leukemia (CML) who lack human leukocyte antigen
(HLA)-identical sibling donors are not offered unrelated marrow transplantation because of concerns over excessive
regimen-related toxicity, in particular due to graft-vs.-host disease (GVHD). The purpose of this study was to
determine the efficacy and toxicity of unrelated marrow transplantation in older CML patients using a regimen
designed to minimize the severity of GVHD. Thirty-one consecutive patients over the age of 40 with CML received
unrelated marrow transplants between January 1988 and June 1997. Twenty-one patients were transplanted in
chronic phase while ten were transplanted in the accelerated phase of their disease. Fifteen patients received trans-
plants from phenotypically matched donors while 16 received marrow grafts from donors who were mismatched at
one HLA locus. GVHD prophylaxis consisted of ex vivo T cell depletion of the donor marrow graft plus posttrans-
plant cyclosporine administration. Durable engraftment was achieved in 29 of 31 patients (94%). The probability of
developing grades II–IV or severe grades III–IV acute GVHD was 39.2 and 7.1%, respectively. There was no differ-
ence in the incidence of grades II–IV acute GVHD between patients transplanted with marrow grafts from pheno-
typically matched (38.1%) vs. those transplanted from mismatched unrelated donors (40%, p  0.99). The 2-year
probability of relapse for the entire population was 29.4%. Relapse was significantly higher for patients transplanted
in accelerated phase (60%) than for those in chronic phase (13.8%, p  0.027). The 2-year probability of overall sur-
vival and disease-free survival for the entire cohort was 56 and 45%, respectively. There was no significant differ-
ence in survival or disease-free survival for patients receiving phenotypically matched vs. mismatched marrow grafts.
Immunological reconstitution for this cohort was compared with a younger (40 years) patient population that had
been similarly transplanted over the same time period. Immune function as assessed by total T cell, B cell, NK cell,
and T cell subset reconstitution posttransplant was quantitatively equivalent in the two groups with most parame-
ters normalizing within 18 months of transplant. We conclude that CML patients over the age of 40 who have either
phenotypically matched or one antigen-mismatched unrelated donors can successfully undergo allogeneic marrow
transplantation. T cell depletion of the marrow graft may be advantageous in these older patients by reducing
GVHD severity, particularly in those patients transplanted with HLA-disparate marrow grafts.
KEY WORDS
Leukemia • Bone marrow transplantation • Unrelated donors
Biology of Blood and Marrow Transplantation 4:3–12 (1998)
© 1998 American Society for Blood and Marrow Transplantation
#97-49.Drobyski.bbmt02
WR Drobyski et al.
4
For many of these patients, unrelated marrow transplanta-
tion has emerged as a viable therapeutic option, albeit at the
expense of increased transplant-related mortality due to
higher rates of graft rejection, more severe graft-vs.-host dis-
ease (GVHD), and an increased frequency of opportunistic
infections [5–7]. These transplant-related complications have
been particularly problematic for older patients (40 years)
undergoing unrelated marrow transplantation [5]. Because
the incidence of CML increases with advancing age, the risk
of these complications affect a substantial portion of poten-
tial candidates for unrelated BMT. Consequently, alternative
approaches, such as interferon therapy or autologous BMT
are often initially considered in these patients by some cen-
ters and unrelated marrow transplantation either not per-
formed or deferred until patients enter the more advanced
phases of CML [8,9]. This is particularly true for patients
who lack phenotypically matched donors and have only mis-
matched unrelated donors from whom to receive marrow
grafts. In an effort to make unrelated marrow transplantation
more effective in this older patient population, we have
designed a transplant regimen to reduce the regimen-related
toxicity of unrelated marrow transplantation by using an
intensive preparative regimen to facilitate durable engraft-
ment along with T cell depletion of the donor graft to
reduce the severity of GVHD. In this study, we present our
results using this approach in 31 patients over the age of 40
with CML who underwent allogeneic marrow transplanta-
tion from both phenotypically matched and mismatched
unrelated marrow donors.
MATERIALS AND METHODS
Patient population
The study population consisted of 31 consecutive
patients over the age of 40 with CML who received bone
marrow transplants from unrelated donors between January
1, 1988, and June 5, 1997, at the Medical College of Wis-
consin. Patient disease status and other demographic data
are shown in Table 1. CML was classiﬁed as being in accel-
erated phase according to previously published criteria [10].
Informed consent was obtained from each patient (or their
guardians) and all treatment was administered under proto-
cols approved by the institutional review committees of the
Medical College of Wisconsin.
Donor selection and histocompatibility testing
Each recipient and donor candidate underwent extended
serotyping for HLA-A, -B, -DR, and -DQ by standard
microcytotoxicity assays. Beginning in February 1989, all
recipients and donors who were judged suitably matched,
based on screening serologic assays, underwent prospective
oligotyping of HLA-DRB1 [11]. Prospective oligotyping for
HLA-DQB1 was begun in January 1990, as previously
described [12]. Donor/recipient pairs from transplants per-
formed before these dates were retrospectively analyzed so
that the degree of HLA-DR and -DQ compatibility for the
entire patient population was evaluable. Additional typing
information was available on 15 donor/recipient pairs from
the retrospective assessment of HLA-A and HLA-B by one-
dimensional isoelectric focusing (IEF [13]) or from solid-
phase DNA sequencing of class I (HLA-A and -B) or class II
(HLA-DR and -DQ) antigens [14,15]. Specifically, eight
patients had class I disparity assessed by IEF, while in two
additional donor/recipient pairs DNA sequencing of HLA-
A and B alleles was performed. Four patients had HLA dis-
parity evaluated by DNA sequencing of both class I and II
alleles in patient and donor, while the remaining patient had
class I and II disparity assessed by IEF and DNA sequencing
(class II only). Any donor/recipient disparity that was
detectable by serology, molecular typing, IEF, or DNA
sequencing was considered a mismatch in this study. Dispar-
ity was categorized based on the highest level of typing
information known at the time of analysis. A greater per-
centage of accelerated-phase patients (7 of 10 [70%])
received mismatched marrow grafts than did chronic-phase
patients (9 of 21 [43%]).
Preparative regimen, GVHD prophylaxis, and supportive care
All patients were treated in laminar air flow or HEPA-
filtered rooms. Pretransplant conditioning consisted of a
regimen of high-dose cytosine arabinoside (3 gm/m2  6,
days –7 to –4), cyclophosphamide (45 mg/kg  2, days –6
and –5), methylprednisolone (1 gm/m2  4, days –2 to 0)
followed by fractionated total-body irradiation to a total
dose of either 13.32 or 14 Gy (days –2 to 0) [10,16].
GVHD prophylaxis consisted of ex vivo T cell depletion
with the  T cell receptor antibody T10B9 plus posttrans-
plant cyclosporine [17]. All patients received prophylactic
acyclovir and trimethoprim-sulfamethoxazole both before
and after transplantation. Cytomegalovirus (CMV)-
seronegative patients received blood components from
CMV-seronegative donors. Twenty-four of the 31 patients
received growth factor therapy with granulocyte colony-
stimulating factor (G-CSF), granulocyte-macrophage
colony-stimulating factor (GM-CSF), or combined G-CSF
and GM-CSF beginning on the day of transplant to accel-
erate myeloid engraftment.
Table 1. Patient characteristics
Sex (M/F) 20/11
Age (years)
Median 45
Range 40–53
Disease status
Chronic phase 21
Diagnosis to BMT 1 year 7
Diagnosis to BMT 1–2 years 6
Diagnosis to BMT 2 years 8
Accelerated phase 10
Donor/recipient histocompatibility
Matched 15
Mismatched 16
A locus 11
B locus 2
DR locus 1
DQ locus 2
Recipient CMV serostatus
Seropositive 16
Seronegative 15
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Assessment of engraftment, GVHD, and relapse
The date of engraftment was deﬁned as the ﬁrst of 3 con-
secutive days in which the absolute neutrophil count (ANC)
was 500/mm3. Trilineage engraftment was documented by
bone marrow examination in the majority of patients 3–4
weeks after transplant. Follow-up marrow studies were done
100 days, 6 months, 1 year, and at least yearly after transplan-
tation to evaluate engraftment and relapse. Durable engraft-
ment was conﬁrmed by cytogenetic analysis, restriction frag-
ment length polymorphism studies, or analysis of a variable
number of tandem repeats in blood or marrow samples to dis-
tinguish donor from recipient cells. Acute GVHD was graded
as 0–IV according to criteria of Glucksberg et al. [18], where-
as chronic GVHD was deﬁned as none, limited, or extensive
[19]. Patients who had evidence of engraftment were evalu-
able for acute GVHD, while patients who engrafted and also
survived more than 100 days were evaluable for chronic
GVHD. Relapse was defined by either morphologic evi-
dence of leukemia in the peripheral blood, marrow, or
extramedullary sites or by the recurrence and sustained pres-
ence of the Philadelphia chromosome (Ph). Patients whose
sole evidence of disease was positivity for the bcr/abl RNA
transcipt by the polymerase chain reaction (PCR) were not
classiﬁed as having relapsed.
PCR assay for detection of minimal residual disease
Total cellular RNA was prepared from peripheral blood,
peripheral blood buffy coats, or peripheral blood mononu-
clear cells isolated by Ficoll-Hypaque (Pel-Freez, Mequon,
WI), bone marrow, or cultured B cells and K562 (Ph) cells.
Based on previous data demonstrating that both are equally
sensitive for detecting residual disease in CML patients [20],
peripheral blood and marrow cells were used interchange-
ably. Cells were either viably frozen or directly added to 4 M
guanidinium isothiocyanate. RNA was prepared from 3 to 5
million cells. The conditions used for extraction of RNA and
PCR ampliﬁcation have been previously detailed [21,22]. All
assays were performed in duplicate, beginning with indepen-
dent RNA isolations. Mock RNA preparations were used as
negative controls in every assay. The criteria used for deﬁn-
ing positive assay results have been previously published [22].
Assay sensitivity was monitored through the addition and
detection of 0.05 ng RNA from the Ph cell line K562,
mixed within a replicate assay for each unknown sample.
This quantity of RNA represents nucleic acid isolated from
approximately ﬁve K562 cells, which requires two rounds of
nested primer PCR for detection.
Immune reconstitution studies
Samples were obtained for immune phenotyping and
proliferative response to T cell and B cell mitogens at 8 tar-
geted posttransplant time points. Sampling periods included
days 30 and 100; 6, 12, and 18 months; and 2, 3, and 4 years.
If a patient was sampled multiple times during an interval,
only the data from the sample nearest to the target time point
was used for analysis. Data were available from 25 of the 31
patients in this study. These data were compared with those
from 36 patients 40 years of age with CML who were simi-
larly transplanted and tested over the same time period.
Lymphocyte subsets were measured by two-color direct
immunophenotyping of ethylene diamine tetraacetic acid
anti-coagulated whole blood samples. Antibodies that were
directly conjugated to phycoerythrin or ﬂuoroscein isothio-
cyanate were obtained from Coulter Immunology (Hialeah,
FL) or Becton Dickinson (Mountain View, CA). The panel
included antibodies to CD45, CD14, CD3, CD4, CD8,
CD56, and CD20, with the appropriate isotype controls.
CD8-positive T cells were deﬁned based on co-expression of
CD3 or T cell receptor-. Either Q-Prep (Coulter
Immunology) or FACS lysis buffer (Becton Dickinson) was
used to lyse red blood cells after antibody staining. Within 24
hours of staining, cells were analyzed using an Epics Proﬁle II
(Coulter Immunology) or a FACSCalibur flow cytometer
(Becton Dickinson). A debris-free lymphocyte gate that was
based on forward- and side-angle light scatter characteristics
was established, and the proportion of stained cells within the
gate for each subset measured. Lymphocyte purity was deter-
mined using CD45 and CD14. Subset percentages were cor-
rected for the percent of CD45cells in the lymphocyte gate.
Data were expressed as the absolute number of the indicated
subset calculated from a white blood cell count (WBC) and
differential performed on the day of sampling as follows: 
Absolute cells per mm3 	 
% of subset in lymphocyte-gated cells 
WBC  % of lymphocytes
Proliferation of mononuclear cells that were isolated
from heparinized peripheral blood to multiple dilutions of
the mitogens phytohemagglutinin-puriﬁed (PHA-P; Difco,
Detroit, MI), concanavalin A (ConA; Aldrich Chemicals,
Milwaukee, WI), and pokeweed mitogen (PWM; Gibco,
Grand Island, NY) was determined. Briefly, lymphocytes
were suspended in RPMI 1640 with 25 
M Hepes (Gibco)
and further supplemented with penicillin/streptomycin and
L-glutamine (Gibco) and 10% heat-inactivated, human AB
serum (locally produced from heparinized plasma). Mitogen-
stimulated cells were plated in triplicate at 105 cells per well
in ﬂat-bottomed 96-well plates, incubated for 72 hours in a
well-humidiﬁed atmosphere of 5% CO2, and pulsed for the
ﬁnal 5 hours of culture with 1 
Ci 3H-thymidine (New Eng-
land Nuclear, Boston, MA) per well. The cells were harvested
onto glass ﬁber ﬁlters and their radioactivity measured in a
liquid scintillation counter (Packard Instruments, Meriden,
CT). Data were expressed as the average counts per minute
(cpm) of triplicate cultures minus the average cpm of cultures
incubated with medium alone. Mitogen concentrations yield-
ing the maximal proliferative response were reported. Two
normal control samples were tested with each mitogen assay.
Statistical analysis
Endpoints were calculated at the date of last contact,
with a latest follow-up date of July 5, 1997. The median
duration of follow-up for the patient population was 51
months (range, 1–87 months). Cumulative actuarial proba-
bilities of relapse, disease-free survival, overall survival, and
acute GVHD were calculated using the Kaplan-Meier
method [23]. Patients were censored at the time of death in
the analysis of acute GVHD. One patient who had graft
rejection was censored at the time of second transplant. A
second patient who rejected the marrow graft and had autol-
ogous reconstitution with return of CML was also classiﬁed
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as having relapsed. Conﬁdence limits for the Kaplan-Meier
estimate were based on the arcsine transformation, using
Greenwood’s formula for the standard error of their survival
estimator [24]. Comparisons of time-to-event distributions
were made using the logrank test and a signiﬁcance level of
0.05. Immune function parameters were compared using an
independent two-tailed Student’s t-test. p 0.01 was consid-
ered signiﬁcant in immune function assays.
RESULTS
Engraftment
The mean bone marrow inoculum administered after 
T cell depletion was 8.6  4.8  107 cells/kg. Limiting dilu-
tion assays were performed in 23 of 31 patients to determine
the degree of T cell depletion. In these patients, the mean log
T cell depletion was 1.6  0.3 and the mean number of
administered T cells was 4.4  6.2  105/kg. All 31 patients
were evaluable for engraftment. Durable engraftment was
achieved in 29 of 31 patients (94%). The median time to an
ANC 500/mm3 for 3 consecutive days was 15 days (range,
9–23 days) in engrafting patients. Two patients had graft
rejection. One patient rejected after having received a mar-
row graft from a phenotypically matched donor, whereas the
second patient rejected after transplantation with a graft from
a donor who was mismatched at one HLA locus (HLA-B).
GVHD
Twenty-nine of 31 patients were evaluable for the devel-
opment of acute GVHD. The probability of developing
grade II–IV acute GVHD was 39.2% (95% conﬁdence inter-
val [CI] 	 23.2–54.9), and the probability of grade III–IV
acute GVHD was 7.1% (95% CI 	 5.7–8.9) in this patient
population (Fig. 1). There was no difference in the incidence
of grade II–IV acute GVHD between patients transplanted
with marrow grafts from phenotypically matched donors
(38.1%) vs. those transplanted from mismatched unrelated
donors (40%, p 	 0.99) (Fig. 2). Twenty-three of 31 patients
survived until day 100 and were evaluable for chronic
GVHD. Limited chronic GVHD occurred in 12 patients;
extensive chronic GVHD developed in four patients. Seven
patients had no evidence of chronic GVHD. The overall
probability of developing extensive chronic GVHD in this
patient population was 18.3% (95% CI 	 12–25.6).
Relapse
The 2-year probability of relapse for the entire cohort
was 29.4% (95% CI 	 16.7–43.3) (Fig. 3). Five patients in
accelerated phase have relapsed while three patients in
chronic phase developed disease recurrence. One of the lat-
ter patients who had rejection of the marrow graft subse-
quently had autologous reconstitution with return of CML.
There was a significantly higher likelihood of relapse for
patients transplanted in accelerated phase (60%) than for
those in chronic phase (13.8%, p 	 0.027). Two patients
who relapsed in accelerated phase were treated with donor
lymphocyte infusions. One patient failed to respond and
died of recurrent disease; the second patient is currently in
remission. One patient who relapsed after undergoing trans-
plantation for chronic-phase disease is currently receiving
therapy with donor lymphocyte infusions but has not yet
responded. There was no difference in relapse rates for
patients transplanted with matched (27%) vs. mismatched
(36%) marrow grafts (p 	 0.92).
All of the 14 patients who were alive and in clinical remis-
sion had samples of either bone marrow or peripheral blood
tested by PCR for the presence of the bcr/abl RNA transcript.
PCR testing was performed to assess the presence of minimal
residual disease in patients who were otherwise in remission. In
13 of 14 patients, this assay was performed within 6 months of
the date of last contact. Twelve of these 14 patients were docu-
mented to be negative for bcr/abl RNA. One of these patients
Figure 1. Actuarial probability of developing grades II–IV or grades III–IV acute GVHD for the entire patient population
Tick marks represent patients who died before developing either  grade II GVHD or  grade III GVHD, respectively.
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was in remission after the administration of donor lymphocyte
infusions for treatment of relapsed disease. The remaining two
patients tested were found to be positive for bcr/abl RNA after
two rounds of nested primer PCR but have not yet demon-
strated any clinical evidence of relapse.
Survival
The 2-year probability of survival was 56% (95% CI 	
29.2–75.9) for the entire cohort of patients. Overall survival
for patients transplanted in accelerated phase (57.1%) was
similar to that for patients transplanted in chronic phase
(54.5%, p 	 0.81). While survival for patients receiving phe-
notypically matched marrow grafts was higher (70%) when
compared with patients receiving mismatched marrow grafts
(42%), this difference was not signiﬁcant (p 	 0.29) (Fig. 4).
Two year disease-free survival was 45% (95% CI 	 25.2–62.8)
for the entire study population. Disease-free survival at two
years was 50 and 28.6% for patients transplanted in chronic
Figure 2. Actuarial probability of developing grades II–IV acute GVHD for patients transplanted with matched or mismatched marrow grafts
Tick marks represent patients who died before developing  grade II acute GHVD.
Figure 3. Actuarial probability of leukemia relapse for the entire patient population
Tick marks represent patients currently in continuous complete remission.
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Figure 4. Actuarial probability of survival for patients transplanted with either matched or mismatched marrow grafts
Tick marks represent patients currently alive.
phase and accelerated phase, respectively ( p 	 0.47). When
comparing patient populations as to whether they received
phenotypically matched or mismatched marrow grafts, dis-
ease-free survival rates were 55 vs. 35%, respectively ( p 	
0.41) (Fig. 5). The performance status of surviving patients is
shown in Table 2.
Cause of death
Infection was the major cause of death (Table 3). Two
patients died of disseminated aspergillosis, one from CMV,
and two from bacterial infections (Pseudomonas bacteremia
and staphylococcal pneumonia). The other primary cause of
death was disease relapse (four patients). No patient died
directly from GVHD; however, all patients who succumbed
to infection had a history of GVHD and were on immuno-
suppressive medications at the time of death. Thus, GVHD
was a likely contributory factor to death in these patients.
Death due to pulmonary hemorrhage, interstitial pneu-
monitis, veno-occlusive disease, and adult respiratory dis-
tress syndrome occurred in one patient each.
Figure 5. Actuarial probability of disease-free survival for patients transplanted with marrow grafts from either phenotypically matched
or mismatched donors
Tick marks represent patients currently alive.
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Immunological reconstitution
Immune reconstitution data was available for 25 of the
40-year-old patients with CML. These results were com-
pared with those from 36 patients with CML who received
unrelated donor marrow transplanted over the same time
period. Not all patients were tested at every time point,
which resulted in similar numbers during each testing inter-
val of patients over and under 40 years of age. The data
shown in Figure 6 represent the median value at each of the
indicated intervals of the patients tested. Total number of
CD3 T cells as well as the CD4 and CD8 T cell subsets
tended to be fewer in the older patient group; however,
these differences were not signiﬁcant at any of the intervals
tested. T cells recovered to the lower limits of normal by
12–18 months with a slightly faster recovery of CD8 T
cells compared with CD4 T cells. CD56 NK cells recov-
ered quickly in both groups and stayed at normal levels, and
B cell numbers normalized at 1 year and overshot the nor-
mal range during subsequent testing intervals. The func-
tional activity of T cells was measured by assessing the pro-
liferative response to T cell mitogens (PHA and ConA) and
to a T and B cell mitogen (PWM). The results were similar
for all three stimuli in that a low normal proliferative
response required 18 or more months to recover (PHA data
shown in Fig. 6; ConA and PWM data are qualitatively the
same as PHA data and are not shown). Results were not
signiﬁcantly different between the two age groups.
DISCUSSION
The major obstacle to successful unrelated marrow
transplantation is the increased risk of transplant-related
mortality when compared with HLA-identical sibling BMT.
Transplant-related mortality has been shown to correlate
with increasing recipient age, signifying that older recipients
are at highest risk from regimen-related toxicity [5,25]. For
these patients to benefit from unrelated BMT, therefore,
reductions in the incidence of graft rejection and severe
GVHD are necessary. The aim of this study was to deter-
mine whether this goal could be accomplished using a trans-
plant regimen that was designed to mitigate the severity of
GVHD without compromising alloengraftment.
The results of this study demonstrate that unrelated
marrow transplantation can be effective therapy for CML
patients over the age of 40. Overall survival and disease-free
survival at 2 years in this older cohort of patients were
approximately 55 and 45%, respectively. These data com-
pare favorably with previously published reports on unre-
lated BMT for CML. For example, a recent analysis from
the National Marrow Donor Program reported a 3-year
disease-free survival of 40% for patients of all ages who
were transplanted in chronic phase [26]. In this study, older
patients had significantly worse outcomes. Furthermore, a
multinational European study recently reported 2–3-year
disease-free survival rates of 55% for pediatric patients
transplanted in the chronic phase of CML [27]. The largest
single center analysis by Anasetti et al. [7], which comprised
both adult and pediatric patients, documented 2.5 year dis-
ease-free survival rates of 52 and 42% for patients trans-
planted in chronic and accelerated phase, respectively.
Thus, older patients in the current study did not appear to
do signiﬁcantly worse than younger patients.
While selection of patients with favorable prognostic
features can be responsible for encouraging results, that was
not a plausible explanation in this study. Rather, most of the
patients presented herein had other adverse prognostic
characteristics in addition to advanced age. For example, the
majority of chronic-phase patients were transplanted more
than 1 year after diagnosis, which has been associated with
reduced survival when compared with patients transplanted
within 1 year of diagnosis [1,3,5]. Furthermore, approxi-
mately 50% of the patients in this study received marrow
grafts from one antigen-mismatched donors, which has been
shown to result in a significantly increased incidence of
severe acute GVHD, chronic GVHD, and treatment-relat-
ed mortality when compared with transplantation with phe-
notypically matched unrelated marrow grafts [28–30].
When all these factors are considered, we believe it is
unlikely that the observed results could be ascribed to favor-
able patient selection.
Although there was no statistical difference in survival
between patients transplanted with matched vs. mismatched
marrow grafts, several points deserve emphasis. First, the
number of patients in this series was small, and therefore the
lack of difference may have been obscured by the small sam-
ple size. Second, more patients who received mismatched
marrow grafts had accelerated-phase disease (7 of 16 vs. 3 of
15) and were therefore at higher risk for adverse outcome.
Third, it is likely that as higher resolution retrospective
DNA sequencing is performed on HLA class I and II alleles,
additional HLA disparities will be revealed, which may mag-
nify the survival differences between the two groups. To that
end, incorporation of the four additional donor/recipient
disparities revealed by IEF or DNA sequencing resulted in
an improvement in 2-year disease-free survival from 45 to
Table 2. Karnokfsky performance status of surviving patients
Score Number of patients (%)
100 6 (35)
90 6 (35)
80 4 (24)
70 1 (6)
Table 3. Causes of death
Number of occurrences
Graft rejection 1
Relapse 4
Infection 5
Aspergillus 2
Cytomegalovirus 1
Bacterial 2
Pulmonary hemorrhage 1
Interstitial pneumonitis 1
Veno-occlusive disease 1
Acute respiratory distress syndrome 1
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55% in patients transplanted with phenotypically matched
marrow grafts and a decline of 45 to 35% in patients who
received mismatched grafts. Thus, these data would lead
one to predict that more deﬁnitive HLA typing will lead to
a further demarcation of these patient cohorts.
The major cause of treatment-related mortality in unre-
lated BMT is GVHD. Conventional prophylaxis for GVHD
in unmodified grafts has typically been with methotrexate
and cyclosporine. With this regimen, severe grades III–IV
acute GVHD have been reported to occur in approximately
50% of patients transplanted with phenotypically matched
grafts and in 70% of recipients transplanted with one anti-
gen-mismatched marrow grafts [28]. To ameliorate the
severity of GVHD, we used ex vivo T cell depletion, which
resulted in a substantial reduction in the incidence and
severity of GVHD. The reduced incidence in GVHD due
to T cell depletion, however, was not counterbalanced by a
marked increase in graft failure. Graft rejection occurred in
only 6% of patients, and the remaining patients had durable
engraftment with no instances of late graft failure. Marrow
graft rejection has been shown to be increased in unrelated
marrow transplantation for CML when compared with that
observed in HLA-identical sibling BMT [31]. Registry
analyses have noted a further increase in non-engraftment
when patients are transplanted with T cell-depleted marrow
grafts [32]. This is thought to be due to radioresistant host
T cells that survive the conditioning regimen and are then
capable of rejecting the graft [33]. To overcome graft resis-
tance, we used a relatively intensive preparative regimen
that was based on prior clinical studies and animal models,
which have shown that graft resistance can be overcome by
augmenting the intensity of the conditioning regimen
[34,35]. This resulted in an incidence of graft rejection that
was somewhat higher than but still comparable with that
observed in patients receiving unmodiﬁed grafts from mis-
matched related and unrelated donors [28].
While there was an approximate 30% 1-year treatment-
related mortality in this patient population, this rate was not
appreciably different from that observed in non–age-select-
ed or younger patient populations [5,7]. The major cause of
death was due to infection similar to that observed in other
series of unrelated BMT. All patients with infection in this
study were on immunosuppressive medications for the
treatment of GVHD, thus implicating GVHD as having a
contributory role in patient death. Relapse was the other
major cause of mortality and occurred with higher frequen-
cy than noted in recipients of non–T cell-depleted grafts
[26]. Disease relapse, however, was much lower in chronic-
phase as opposed to accelerated-phase patients in whom
there appeared to be relative preservation of an
antileukemic effect [22]. That the vast majority of chronic-
phase patients who were in clinical remission were also in
molecular remission supports this contention. Based on our
previous observation that PCR testing is highly predictive
for subsequent relapse in these patients [36], we predict that
the majority of these patients would remain in remission.
For accelerated-phase patients, additional strategies such as
posttransplant cellular immunotherapy [37,38] may be war-
ranted to reduce the higher relapse rate. The use of mis-
matched marrow grafts did not confer an additional graft-
vs.-leukemia effect, but patient numbers may not have been
sufﬁcient to detect such a difference.
Successful outcomes after unrelated BMT are contin-
gent on effective immunological reconstitution, which is
necessary to prevent the development of opportunistic
infections. Since older age has been associated with delayed
recovery of immune function [39], we compared parameters
of immune reconstitution between the present cohort and a
group of similarly transplanted younger patients with CML.
We observed no significant differences between these two
groups, indicating that transplantation of older patients did
not result in a further delay in immune recovery. Thus,
although T cell depletion has been associated with a delay in
immune reconstitution [40], the use of T cell depletion in
these older patients did not preclude the normalization of
these parameters, nor did the tempo lag behind that
observed in younger patients.
In summary, we conclude from these data that patients
between the ages of 40 and 50 need not be a priori excluded
Figure 6. Immune reconstitution after unrelated donor transplanta-
tion for CML
Shown are data from 25 patients 40 years () and 36 patients 40 years
(), transplanted with T cell-depleted marrow from an unrelated donor for the
treatment of CML. If a patient was sampled more than once during the indi-
cated interval, only the sample closest to the target time point was included. Not
all patients were tested at each target time point. Data are presented as the
median cells per mm3 for the indicated lymphocyte subset and the median counts
per minute of 3H-thymidine for cultures stimulated with PHA. The 5th and
95th percentile of simultaneously tested normal control individuals are shown as
the open rectangles. The number of patients sampled during each interval for
patients 40 and 40, respectively, were: 2 months, 16 and 22; 3 months,
21 and 22; 6 months, 18 and 17; 12 months, 15 and 15; 18 months, 9 and 7;
24 months, 9 and 6; 36 months, 7 and 7; 48 months, 5 and 5.
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from receiving unrelated marrow grafts because of concern
that they will have excessive transplant-related toxicity.
While regimen-related mortality is higher than in HLA-
identical sibling marrow transplantation, patients who lack
HLA-identical sibling donors can be considered suitable can-
didates for unrelated marrow transplantation, and a sizable
portion can be expected to have long-term survival. The use
of T cell depletion allowed for a reduction in the severity of
GVHD and may be advantageous in older patients, particu-
larly those transplanted with HLA-disparate marrow grafts.
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